Antibody-drug conjugate containing thiazolo[5,4-b]pyridine structure and use thereof
IL330726A0Pending Publication Date: 2026-08-01BEIJING TIDE PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- IL330726
- Authority / Receiving Office
- IL · IL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-17
- Filing Date
- 2025-01-16
- Publication Date
- 2026-08-01
AI Technical Summary
Technical Problem
Existing antibody-conjugated drug (ADC) linkers are unstable in vivo, causing cytotoxins to off-target, reduce drug efficacy and increase toxicity, and there is room for optimization of linker design.
Method used
A thiol-reactive linker with 2-(methylsulfonyl)thiazole[5,4-b]pyridine structure is used to connect antibodies and cytotoxins, improve the stability and hydrophilicity of the linker, and is suitable for coupling of a variety of biomolecular molecules.
Benefits of technology
It enhances the stability and efficacy of antibody-conjugated drugs, reduces off-target toxicity, and improves the effective load release of the drug in target tissue.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a new thiol-reactive coupling moiety as shown in formula (I), a linker containing the coupling moiety, a linker-payload conjugate, an antibody-drug conjugate based on the linker and the use thereof, and further relates to a pharmaceutical composition containing the antibody-drug conjugate, and the use of the antibody-drug conjugate for treating and / or preventing a disease.
Need to check novelty before this filing date? Find Prior Art